These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7509126)

  • 1. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Condray R; Peters JL
    Neuropsychopharmacology; 1996 Apr; 14(4):275-83. PubMed ID: 8924195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal.
    van Kammen DP; Yao J; Gurklis J; O'Connor D; Nofzinger E; Peters JL
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():325A-326A. PubMed ID: 1498856
    [No Abstract]   [Full Text] [Related]  

  • 9. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia.
    Forman SD; Bissette G; Yao J; Nemeroff CB; van Kammen DP
    Schizophr Res; 1994 Apr; 12(1):43-51. PubMed ID: 8018584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
    McAllister CG; van Kammen DP; Rehn TJ; Miller AL; Gurklis J; Kelley ME; Yao J; Peters JL
    Am J Psychiatry; 1995 Sep; 152(9):1291-7. PubMed ID: 7653683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Norepinephrine turnover under neuroleptic treatment of schizophrenic syndromes (author's transl)].
    Eben E; Ackenheil M; Rüther E
    Arzneimittelforschung; 1978; 28(9):1498. PubMed ID: 38809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
    van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
    Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
    Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
    Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting haloperidol treatment response in chronic schizophrenia.
    van Kammen DP; Kelley ME; Yao JK; Gilbertson MW; Gurklis JA; Inosaka T; Saito H; Peters JL; Sato M
    Psychiatry Res; 1996 Aug; 64(1):47-58. PubMed ID: 8888364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
    Neylan TC; van Kammen DP; Kelley ME; Peters JL
    Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate challenge as a predictor of relapse in schizophrenia.
    Lieberman JA; Kane JM; Gadaleta D; Brenner R; Lesser MS; Kinon B
    Am J Psychiatry; 1984 May; 141(5):633-8. PubMed ID: 6143506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.